ARS Pharmaceuticals (SPRY) Insider Schneider Buys 30,000 Shares
Phillip Schneider recently acquired 30,000 shares of ARS Pharmaceuticals, Inc.
Reviewed by automated data checks against the source filing. How we make and check alerts
Phillip Schneider bought 30,000 shares of ARS Pharmaceuticals, Inc. ($SPRY) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $SPRY is down 24.7% after 1 week, down 43.6% after 1 month and down 61.9% to date (from the $10.54 close on Jun 24, 2026).
SPRY
ARS Pharmaceuticals, Inc.
Key Points
- Phillip Schneider purchased 30,000 shares of ARS Pharmaceuticals on June 24, 2026.
- Shares of ARS Pharmaceuticals traded at $8.54 on Saturday, with a market cap of $848 million.
- Analysts maintain a strong buy consensus with a mean price target of $28.4.
Get $SPRY trade alerts by text
We text you when insiders, Congress or big funds trade $SPRY. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ARS Pharmaceuticals, Inc. alert may contain errors. Disclosures
Phillip Schneider made a move in the stock market by purchasing 30,000 shares of ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY) on June 24, 2026. This insider transaction wasn't part of a pre-planned program, indicating a direct investment choice by Schneider.
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
Several insiders at ARS Pharmaceuticals have been active in the market. On June 24, along with Phillip Schneider, insiders like Peter Thompson, Laura Shawver, and Rajeev Dadoo each bought 30,000 shares. These transactions, like Schneider's, were not under any pre-planned trading programs.
ARS Pharmaceuticals, Inc. Stock Up 107.8%
On Saturday, ARS Pharmaceuticals' shares were trading at $8.54. The company has a market cap of approximately $848 million. With a forward P/E ratio currently not meaningful due to lack of profitability, the biotech firm has a beta of 0.826, suggesting lower volatility compared to the market. Over the past year, the stock has seen a low of $6.66 and a high of $18.90, with a current 50-day moving average of $8.70 and a 200-day moving average of $9.36.
Analysts Set New Price Targets
Analyst firms remain optimistic about ARS Pharmaceuticals. On June 25, 2026, Leerink Partners maintained its buy rating with a price target of $24. Cantor Fitzgerald also maintained a buy rating, setting a target of $30 in their May 28, 2026 report. Overall, the stock has a strong buy consensus with an average target price of $28.4, based on five analyst opinions.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biotech company based in San Diego, California. Founded in 2015, the company focuses on developing treatments for severe allergic reactions. Its main product, Neffy, is an intranasal delivery system for epinephrine, offering a needle-free solution for emergency treatment of Type I allergic reactions, including anaphylaxis. The company employs 154 people and is led by CEO Richard E. Lowenthal.
Bottom Line
Phillip Schneider's recent purchase of ARS Pharmaceuticals shares is part of a broader trend of insider buying at the company. With shares trading at $8.54 and a market cap of $848 million, ARS Pharmaceuticals continues to attract attention from both insiders and analysts. Investors will be watching closely as the company progresses with its innovative treatments. Remember, insider transactions like these are reported after the fact and don't necessarily indicate future performance.
Related Filing Alerts
Source: Phillip Schneider's Form 4 filing on $SPRY (Jun 24, 2026). Find the original filing: SPRY Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts